RxDoctor Payments Data

Casey Brown, NP

Psychiatric/Mental Health · Lakewood, NYNPI 1255964268

Payments from drug & device makers

$3,673in general payments, 2019–2025

Across 153 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$956
  • AbbVie$668
  • Alkermes, Inc.$522
  • Otsuka America Pharmaceutical, Inc.$308
  • Neurocrine Biosciences, Inc.$293
  • Lundbeck LLC$187
  • plus $738 from 9 others

What the payments were for

  • Food & beverage$3,661100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,673 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$22,467
Medicare patients
153
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate60$194,325
VraylarCariprazine Hcl22$31,929
Aripiprazole356$31,176
RexultiBrexpiprazole19$27,147
NuedextaDextromethorphan Hbr/Quinidine13$21,284
Seroquel XrQuetiapine Fumarate16$16,059
Clomipramine Hcl22$8,146
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$6,474
Lurasidone Hcl41$6,289
Vilazodone Hcl45$5,959
Olanzapine OdtOlanzapine54$5,569
Quetiapine Fumarate335$4,892
Fluphenazine Hcl21$4,489
Clozapine39$4,421
Fluvoxamine Maleate101$3,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$173$194,32560 claims
AbbVieVraylar$668$31,92922 claims
Otsuka America Pharmaceutical, Inc.Rexulti$308$27,14719 claims
Indivior Inc.Suboxone$139$6,47412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Lakewood

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →